Compendium of Cancer Genome Aberrations

Changes

HAEM5:Follicular lymphoma (view source)

Revision as of 15:34, 20 December 2023

1,131 bytes added ,  15:34, 20 December 2023
→‎Cancer Sub-Classification / Subtype
Line 1: Line 1:  
{{DISPLAYTITLE:Follicular lymphoma}}
 
{{DISPLAYTITLE:Follicular lymphoma}}
 +
 
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (5th ed.)]]
 
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (5th ed.)]]
    
{{Under Construction}}
 
{{Under Construction}}
   −
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Follicular Lymphoma]].
+
<blockquote class="blockedit">{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Follicular Lymphoma]].
 
Other relevent pages include: [[HAEM4:Testicular Follicular Lymphoma]]
 
Other relevent pages include: [[HAEM4:Testicular Follicular Lymphoma]]
    
Note: autho needs to correlate with Testicular Follicular Lymphoma
 
Note: autho needs to correlate with Testicular Follicular Lymphoma
 
}}</blockquote>
 
}}</blockquote>
 +
 +
<span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span>
 +
 
==Primary Author(s)*==
 
==Primary Author(s)*==
   Line 22: Line 26:     
==Cancer Sub-Classification / Subtype==
 
==Cancer Sub-Classification / Subtype==
 +
 +
''In situ'' FL,
 +
 +
Duodenal-type FL,
 +
 +
Pediatric FL,
    
Follicular Lymphoma
 
Follicular Lymphoma
Line 83: Line 93:       −
<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}}
+
<blockquote class="blockedit">{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}}
      Line 93: Line 103:       −
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 2, 3, 4]</blockquote>
+
<blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 2, 3, 4]</blockquote>
 
</blockquote>
 
</blockquote>
 
==Sites of Involvement==
 
==Sites of Involvement==
Line 101: Line 111:       −
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 2, 3, 4]</blockquote>
+
<blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 2, 3, 4]</blockquote>
 
==Morphologic Features==
 
==Morphologic Features==
   Line 109: Line 119:  
Consists of both centrocytes and centroblasts, with the relative proportions of these cells informing grading
 
Consists of both centrocytes and centroblasts, with the relative proportions of these cells informing grading
   −
Grade I:   0-5 centroblasts/high power field (hpf)
+
Grade 1:   0-5 centroblasts/high power field (hpf)
   −
Grade II:  6-15 centroblasts/hpf
+
Grade 2:  6-15 centroblasts/hpf
    
Grade III: >15 centroblasts/hpf
 
Grade III: >15 centroblasts/hpf
Line 120: Line 130:       −
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 2, 3, 4]</blockquote>
+
<blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 2, 3, 4]</blockquote>
 
==Immunophenotype==
 
==Immunophenotype==
   Line 140: Line 150:       −
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 9, 10]</blockquote>
+
<blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 9, 10]</blockquote>
 
==Chromosomal Rearrangements (Gene Fusions)==
 
==Chromosomal Rearrangements (Gene Fusions)==
   Line 164: Line 174:  
 
   −
<blockquote class='blockedit'>{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}
+
<blockquote class="blockedit">{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}
      Line 181: Line 191:  
 
   −
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 2, 5, 7, 9, 11]</blockquote>
+
<blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 2, 5, 7, 9, 11]</blockquote>
 
</blockquote>
 
</blockquote>
      −
<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).|Please incorporate this section into the relevant tables found in:
+
<blockquote class="blockedit">{{Box-round|title=v4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).|Please incorporate this section into the relevant tables found in:
 
* Chromosomal Rearrangements (Gene Fusions)
 
* Chromosomal Rearrangements (Gene Fusions)
 
* Individual Region Genomic Gain/Loss/LOH
 
* Individual Region Genomic Gain/Loss/LOH
Line 243: Line 253:  
|}
 
|}
   −
<blockquote class='blockedit'>{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}
+
<blockquote class="blockedit">{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}
    
deletions in 1p36, 6q, 10q, 13p, 17p; gains of 1q, 2p, 7, 8, 12q, 18q
 
deletions in 1p36, 6q, 10q, 13p, 17p; gains of 1q, 2p, 7, 8, 12q, 18q
Line 270: Line 280:  
|}
 
|}
   −
<blockquote class='blockedit'>{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}
+
<blockquote class="blockedit">{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}
      Line 276: Line 286:       −
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[11]</blockquote>
+
<blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[11]</blockquote>
 
</blockquote>
 
</blockquote>
 
==Gene Mutations (SNV / INDEL)==
 
==Gene Mutations (SNV / INDEL)==
Line 312: Line 322:       −
<blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}
+
<blockquote class="blockedit">{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}
    
Put your text here and/or fill in the tables
 
Put your text here and/or fill in the tables
Line 384: Line 394:  
|}
 
|}
   −
<blockquote class='blockedit'>{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}
+
<blockquote class="blockedit">{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}
    
''BCR-NFκB'', ''JAK/STAT''; ''mTORC'' signaling
 
''BCR-NFκB'', ''JAK/STAT''; ''mTORC'' signaling
Line 415: Line 425:  
(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted.''</span> <span style="color:#0070C0">''If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">) </span> <references />
 
(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted.''</span> <span style="color:#0070C0">''If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">) </span> <references />
   −
'''
+
<br />
    
==Notes==
 
==Notes==
Line 421: Line 431:     
<nowiki>*</nowiki>''Citation of this Page'': “Follicular lymphoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Follicular_lymphoma</nowiki>.
 
<nowiki>*</nowiki>''Citation of this Page'': “Follicular lymphoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Follicular_lymphoma</nowiki>.
−
[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases F]]
+
[[Category:HAEM5]]
 +
[[Category:DISEASE]]
 +
[[Category:Diseases F]]
Retrieved from "https://ccga.io/index.php/Special:MobileDiff/13537...13956"